KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Payables (2018 - 2025)

Historic Payables for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $512.4 million.

  • BioNTech SE's Payables fell 3881.85% to $512.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $512.4 million, marking a year-over-year decrease of 3881.85%. This contributed to the annual value of $456.0 million for FY2024, which is 1894.11% up from last year.
  • Per BioNTech SE's latest filing, its Payables stood at $512.4 million for Q3 2025, which was down 3881.85% from $615.4 million recorded in Q2 2025.
  • BioNTech SE's 5-year Payables high stood at $949.3 million for Q2 2024, and its period low was $32.1 million during Q1 2023.
  • Its 5-year average for Payables is $434.0 million, with a median of $398.4 million in 2021.
  • In the last 5 years, BioNTech SE's Payables tumbled by 8975.47% in 2023 and then surged by 91923.9% in 2024.
  • BioNTech SE's Payables (Quarter) stood at $379.3 million in 2021, then plummeted by 45.11% to $208.2 million in 2022, then surged by 84.1% to $383.4 million in 2023, then grew by 18.94% to $456.0 million in 2024, then increased by 12.38% to $512.4 million in 2025.
  • Its Payables was $512.4 million in Q3 2025, compared to $615.4 million in Q2 2025 and $515.4 million in Q1 2025.